[Telbivudine in the treatment of the chronic B hepatitis].
Butí
María Asunción
MA
Servicio de Hepatología, Hospital General Universitario Vall d'Hebron, Barcelona, Spain. mbuti@vhebron.net
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological / Q000097:blood; D001711:Biotransformation; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D024882:Drug Resistance, Viral; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D009705:Nucleosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010766:Phosphorylation; D011355:Prodrugs / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D054316:Biomarkers, Pharmacological; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D011355:Prodrugs; D011744:Pyrimidinones; D000077712:Telbivudine; D019259:Lamivudine; D013936:Thymidine